| Tumour burden and efficacy of immune-checkpoint inhibitors FG Dall’Olio, A Marabelle, C Caramella, C Garcia, M Aldea, N Chaput, ... Nature reviews Clinical oncology 19 (2), 75-90, 2022 | 219 | 2022 |
| Overcoming resistance to tumor-targeted and immune-targeted therapies M Aldea, F Andre, A Marabelle, S Dogan, F Barlesi, JC Soria Cancer Discovery 11 (4), 874-899, 2021 | 191 | 2021 |
| Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells C Tomuleasa, O Soritau, A Orza, M Dudea, B Petrushev, O Mosteanu, ... J Gastrointestin Liver Dis 21 (2), 187-196, 2012 | 140 | 2012 |
| Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC MV Negrao, HA Araujo, G Lamberti, AJ Cooper, NS Akhave, T Zhou, ... Cancer discovery 13 (7), 1556-1571, 2023 | 101 | 2023 |
| How to manage patients with corticosteroids in oncology in the era of immunotherapy? M Aldea, E Orillard, L Mansi, A Marabelle, F Scotte, O Lambotte, ... European Journal of Cancer 141, 239-251, 2020 | 83 | 2020 |
| Small cell lung cancer: a slightly less orphan disease after immunotherapy J Remon, M Aldea, B Besse, D Planchard, M Reck, G Giaccone, JC Soria Annals of Oncology 32 (6), 698-709, 2021 | 75 | 2021 |
| Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression M Aldea, L Hendriks, L Mezquita, C Jovelet, D Planchard, E Auclin, ... Journal of Thoracic Oncology 15 (3), 383-391, 2020 | 71 | 2020 |
| Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells MD Aldea, B Petrushev, O Soritau, CI Tomuleasa, I Berindan-Neagoe, ... J buon 19 (2), 502-511, 2014 | 64 | 2014 |
| Glioblastoma stem cells: a new target for metformin and arsenic trioxide M Carmignani, AR Volpe, M Aldea, O Soritau, A Irimie, IS Florian, ... J Biol Regul Homeost Agents 28 (1), 1-15, 2014 | 59 | 2014 |
| Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery M Aldea, L Craciun, C Tomuleasa, I Berindan-Neagoe, G Kacso, ... Tumor Biology 35, 5101-5110, 2014 | 55 | 2014 |
| Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas O Soritau, C Tomuleasa, M Aldea, B Petrushev, S Susman, D Gheban, ... J buon 16 (2), 282-289, 2011 | 55 | 2011 |
| The role of depression and neuroimmune axis in the prognosis of cancer patients M Aldea, L Craciun, C Tomuleasa, C Crivii J BUON 19 (1), 5-14, 2014 | 44 | 2014 |
| Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma B Petrushev, C Tomuleasa, O Soritau, M Aldea, T Pop, S Susman, ... Experimental Oncology, 2012 | 41 | 2012 |
| Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study A Bayle, L Belcaid, M Aldea, D Vasseur, F Peyraud, C Nicotra, A Geraud, ... Annals of Oncology 34 (4), 389-396, 2023 | 39 | 2023 |
| Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small … S Ortiz-Cuaran, L Mezquita, A Swalduz, M Aldea, J Mazieres, C Leonce, ... Clinical Cancer Research 26 (23), 6242-6253, 2020 | 38 | 2020 |
| Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma C Tomuleasa, O Soritau, E Fischer-Fodor, T Pop, S Susman, O Mosteanu, ... Hematology/Oncology and Stem Cell Therapy 4 (2), 60-66, 2011 | 36 | 2011 |
| Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19 M Aldea, JM Michot, FX Danlos, A Ribas, JC Soria Cancer Discovery 11 (6), 1336-1344, 2021 | 33 | 2021 |
| RET-MAP: an international multicenter study on Clinicobiologic features and treatment response in patients with lung cancer harboring a RET fusion M Aldea, A Marinello, M Duruisseaux, W Zrafi, N Conci, G Massa, G Metro, ... Journal of Thoracic Oncology 18 (5), 576-586, 2023 | 32 | 2023 |
| Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 2021; 11: 874–899. doi: 10.1158/2159-8290 M Aldea, F Andre, A Marabelle, S Dogan, F Barlesi, JC Soria CD-20-1638.[Abstract][CrossRef][Academic Search], 0 | 29 | |
| Nanoparticles for targeting intratumoral hypoxia: exploiting a potential weakness of glioblastoma M Aldea, IA Florian, G Kacso, L Craciun, S Boca, O Soritau, IS Florian Pharmaceutical research 33, 2059-2077, 2016 | 26 | 2016 |
